AT845
Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset
Explore 12 assets in Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Astellas Gene Therapies
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04174105CT.gov Gene Transfer Study in Patients With Late Onset Pompe Disease | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| AT845 (this asset) | Astellas Gene Therapies | P1/2 | CC · 47 |
| Alglucosidase Alfa | Erasmus Medical Center | P4 | BBB |
| Cipaglucosidase Alfa | Amicus Therapeutics | P3 | BB |
| Avalglucosidase Alfa | Iris Plug | P4 | BB |
| Miglustat | Amicus Therapeutics | P3 | B |
| at2221 | Amicus Therapeutics | P3 | B |
| Clenbuterol | Duke University | P2 | CCC |
| gc301 | GeneCradle Inc | P1/2 | CC |
| ab-1009 | AskBio Inc | P1/2 | CC |
+5 more in the Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. AT845 in Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/at845-glycogen-storage-disease-due-to-acid-maltase-deficiency-late-onset
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →